Nusayba Bagegni Receives NCI Early Career Award for Breast Cancer Research
核心洞察
Dr. Nusayba Bagegni, a medical oncologist at Washington University, has received the 2024 Early Career Cancer Clinical Investigator Award from the NCI.
Bagegni's research focuses on aggressive breast cancer (搜索) subtypes, breast cancer in younger women, metastatic breast cancer (搜索), and developmental therapeutics.
As associate medical director of clinical research, she leads breast cancer (搜索) clinical trials at Siteman Cancer Center (搜索), focusing on early-stage and advanced disease.
Nusayba Bagegni, MD, an associate professor of medicine at Washington University School of Medicine in St. Louis, has been awarded the prestigious 2024 Early Career Cancer Clinical Investigator Award from the National Cancer Institute (NCI). This award recognizes her significant contributions and future potential in breast cancer (搜索) clinical research.
Focus on Aggressive Breast Cancers
Dr. Bagegni's clinical and research efforts are primarily dedicated to improving outcomes for patients with breast cancer (搜索). Her specific interests include aggressive breast cancer subtypes, breast cancer in younger women, metastatic breast cancer (搜索), and developmental therapeutics. She is actively involved in designing and leading clinical trials aimed at addressing the unmet needs of these patient populations.
Leadership in Clinical Trials
At Siteman Cancer Center (搜索), based at Barnes-Jewish Hospital and WashU Medicine (搜索), Dr. Bagegni serves as the associate medical director of clinical research in the Division of Oncology. In this role, she leads the breast cancer (搜索) clinical trials portfolio, overseeing the development and implementation of studies for both early-stage and advanced breast cancer. Her leadership is crucial in bringing innovative treatments to patients in the St. Louis region and beyond.